NEW YORK (GenomeWeb News) – Protagen today said that Bayer HealthCare will evaluate the firm’s UNIarray technology for discovering biomarkers for patient stratification and predictive diagnosis of atrial fibrillation.
Protagen’s UNIarray is designed to help develop diagnostics based on indication-specific autoantibody patterns in blood samples. The firm said that such autoantibody patterns are present not only in several autoimmune diseases but also in cancer, neurodegenerative disorders, and some healthy individuals.
Bayer HealthCare is currently studying atrial fibrillation after heart surgery, a condition that cannot be predicted with current diagnostic tools, Protagen said.
The firms did not say how long the evaluation period would last, and they did not disclose any financial terms of the pact.